[1]刘延方,白俊俊,王树娟,等.伴13q14缺失的初诊多发性骨髓瘤患者的临床特征和治疗反应[J].郑州大学学报(医学版),2019,(01):110-114.[doi:10.13705/j.issn.1671-6825.2018.07.123]
 LIU Yanfang,BAI Junjun,WANG Shujuan,et al.Clinical features and response to therapies in de novo multiple myeloma patients with 13q14 deletion[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2019,(01):110-114.[doi:10.13705/j.issn.1671-6825.2018.07.123]
点击复制

伴13q14缺失的初诊多发性骨髓瘤患者的临床特征和治疗反应()
分享到:

《郑州大学学报(医学版)》[ISSN:1671-6825/CN:41-1340/R]

卷:
期数:
2019年01期
页码:
110-114
栏目:
应用研究
出版日期:
2019-01-20

文章信息/Info

Title:
Clinical features and response to therapies in de novo multiple myeloma patients with 13q14 deletion
作者:
刘延方白俊俊王树娟郝倩倩王 冲侯降雪郭程娱廖林晓孙 慧孙 玲汤 平王 萌姜中兴万鼎铭
郑州大学第一附属医院血液科 郑州 450052
Author(s):
LIU Yanfang BAI Junjun WANG Shujuan HAO Qianqian WANG Chong HOU Jiangxue GUO Chengyu LIAO Linxiao SUN Hui SUN Ling TANG Ping WANG Meng JIANG Zhongxing WAN Dingming
Department of Hematology, the First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052
关键词:
多发性骨髓瘤 13q14缺失 硼替佐米 预后
Keywords:
multiple myeloma 13q14 deletion bortezomib prognosis
分类号:
R733.3
DOI:
10.13705/j.issn.1671-6825.2018.07.123
摘要:
目的:探讨伴13q14缺失的初诊多发性骨髓瘤(MM)患者的临床特征和治疗反应。方法:选择初诊MM患者251例,利用荧光原位杂交技术检测其13q14异常情况,应用Kaplan-Meier生存曲线和Cox回归分析13q14缺失对预后的影响。结果:251例中,13q14缺失80例(31.9%)。13q14缺失组初诊时血清钙离子、β2MG、M蛋白水平及骨髓浆细胞水平高于未缺失组,血红蛋白、血小板水平低于未缺失组,DSⅢ期患者比例、ISSⅢ期患者比例均高于未缺失组(P<0.05)。2组OS和PFS生存曲线比较结果显示,13q14缺失组预后差于未缺失组(P<0.05)。Cox回归分析结果显示,13q14缺失是PFS和OS的独立危险因素,HR(95%CI)分别为1.7(1.1~2.7)和2.3(1.2~4.5)。治疗1个疗程、4个疗程后,BD方案组M蛋白下降率均高于传统方案组(P均<0.05)。结论:伴13q14缺失的MM患者初诊时肿瘤负荷高,整体预后差; 含硼替佐米方案可改善其预后。
Abstract:
Aim:To investigate the clinical features and response to therapies in de novo multiple myeloma(MM)patients with 13q14 deletion[del(13q14)].Methods:Clinical data of 251 newly diagnosed MM patients were analyzed retrospectively. The fluorescent in situ hybridization was used for detection of del(13q14), and Kaplan-Meier survival curve and Cox regression were used to study the effects of del(13q14)on MM prognosis.Results:Among the 251 patients, del(13q14)was observed in 80(31.9%)cases. The levels of serum calcium, β2 microglobulin,M protein and marrow plasma cells of the del(13q14)group were higher than those of the non-del(13q14)group, while hemoglobin and platelets were lower, and the proportions of patients in DSⅢ stage or ISSⅢ stage were higher(P<0.05)at the initial diagnosis. The results of Kaplan-Meier survival analysis showed that the prognosis of the del(13q14)group was worse than that of the non-del(13q14)group(P<0.05).Cox regression analysis showed that the del(13q14)was an independent risk factor for PFS and OS,HR(95%CI)was 1.7(1.1-2.7)and 2.3(1.2-4.5). After 1 or 4 courses of treatment,the descending rate of M protein in BD regimen group was higher than traditional regimen group(P<0.05).Conclusion:MM patients with del(13q14)have higher tumor burden at the initial diagnosis and have worse prognosis.Bortezomib regimen could improve the prognosis.

参考文献/References:

[1] SAXE D, SEO EJ, BERGERON MB, et al. Recent advances in cytogenetic characterization of multiple myeloma[J].Int J Lab Hematol,2018.doi:10.1111/ijlh.12882
[2] KAPOOR P,FONSECA R,RAJKUMAR SV,et al.Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapies[J].Mayo Clin Proc,2010,85(6):532
[3] FACON T,AVET-LOISEAU H,GUILLERM G,et al.Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy[J].Blood,2001,97(6):1566
[4] 中国医师协会血液科医师分会,中华医学会血液学分会,中国医师协会多发性骨髓瘤专业委员会.中国多发性骨髓瘤诊治指南:2017年修订[J].中华内科杂志,2017,56(11):866
[5] 杨强,侯健,陈文明,等.双克隆免疫球蛋白多发性骨髓瘤六例报告并文献复习[J].中华血液学杂志,2016,37(7):614
[6] ZOJER N,KONIGSBERG R,ACKERMANN J,et al.Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization[J].Blood,2000,95(6):1925
[7] OH S,KOO DH,KWON MJ,et al.Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study[J].Ann Hematol,2014,93(8):1353
[8] AVET-LOISEAU H,SOULIER J,FERMAND JP,et al.Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone[J].Leukemia,2010,24(3):623
[9] JUNG HA,JANG MA,KIM K,et al.Clinical utility of a diagnostic approach to detect genetic abnormalities in multiple myeloma: a single institution experience[J].Ann Lab Med,2018,38(3):196
[10]GRZASKO N,HAJEK R,HUS M,et al.Chromosome 1 amplification has similar prognostic value to del(17p13)and t(4; 14)(p16; q32)in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group[J].Leuk Lymphoma,2017,58(9):2089
[11]AVET-LOISEAU H,ATTAL M,CAMPION L,et al.Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4; 14), del(17p), 1q gains] play a major role in defining long-term survival[J].J Clin Oncol,2012,30(16):1949
[12]SHIN SY,EOM HS,SOHN JY,et al.Prognostic implications of monosomies in patients with multiple myeloma[J].Clin Lymphoma Myeloma Leuk,2017,17(3):159
[13]DIMOPOULOS MA,ORLOWSKI RZ,FACON T,et al.Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma[J].Haematologica,2015,100(1):100
[14]XIAO GW,LI YQ,WANG YY,et al.LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity[J].Exp Cell Res,2018,370(2):254

相似文献/References:

[1]胡杰英),蒋东霞),范瑞华),等.多发性骨髓瘤14例间期荧光原位杂交分析[J].郑州大学学报(医学版),2010,(04):659.
 [J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2010,(01):659.
[2]革化民,崔静,刘保平#,等.骨显像和CT诊断多发性骨髓瘤骨质破坏的比较革化民[J].郑州大学学报(医学版),2010,(06):1031.
[3]戴豫苏,孙 玲#,孙 慧,等.硼替佐米联合地塞米松及沙利度胺治疗多发性骨髓瘤的临床疗效戴豫苏,孙 玲,孙 慧,陈绍倩,刘林湘,[J].郑州大学学报(医学版),2016,(04):554.
[4]王 芳 ),吴 歌 ),张珊珊),等.多发性骨髓瘤合并肾损害患者临床及病理特征分析[J].郑州大学学报(医学版),2019,(04):631.[doi:10.13705/j.issn.1671-6825.2018.09.136]
 WANG Fang),WU Ge),ZHANG Shanshan),et al.Clinical and pathological features of patients with multiple myeloma complicated with renal impairment[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2019,(01):631.[doi:10.13705/j.issn.1671-6825.2018.09.136]

备注/Memo

备注/Memo:
【基金项目】国家自然科学基金资助项目(81400108,U1504806) 【作者简介】刘延方,通信作者,男,1962年5月生,博士,教授,主任医师,研究方向:血液病的基础与临床,E-mail:liuyf371@163.com
更新日期/Last Update: 2019-01-20